Agoracom Blog Home

Posts Tagged ‘MMJ’

North Bud Farms $NBUD.ca Announces Licensing of #Cannabinoid Infusion Technology for Food and Beverage Platform $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 4:13 PM on Thursday, September 27th, 2018

Northbud large

  • Announced the licensing of infusion technology for its food and beverage platform with Made By Science Inc., a wholly owned subsidiary of Form Factory Inc.
  • Company signed a supply and licensing agreement with Made By Science Inc. , an Oregon, California multi state co-packaging and infused product manufacturer.
  • MBS owns a variety of IP protected infusion, encapsulation, taste masking and manufacturing processes

TORONTO, Sept. 27, 2018 – North Bud Farms Inc. (CSE: NBUD) (“NORTHBUD” or the “Company”) is pleased to announce the licensing of infusion technology for its food and beverage platform with Made By Science Inc., a wholly owned subsidiary of Form Factory Inc.

The Company signed a supply and licensing agreement with Made By Science Inc. (“MBS”), an Oregon, California multi state co-packaging and infused product manufacturer. MBS owns a variety of IP protected infusion, encapsulation, taste masking and manufacturing processes.

This Agreement provides that NORTHBUD will purchase from MBS raw, non-infused protein-based encapsulation powder (MX-17) to be used for infusion and formulation purposes in the Canadian market. NORTHBUD and MBS have established a per gram cost as well as a royalty agreement where NORTHBUD will pay a floating royalty on business to business sales and a consumer direct sale.

The companies intend to negotiate a master licensing agreement (“the Agreement”) to include the licensing and use of multiple proprietary food infusion technologies for which MBS will grant a master license for NORTHBUD to the use of the patented technology.

“Over the past 8 months our team has researched many technology solutions pertaining to encapsulation and infusion of cannabinoids into foods and beverages,” said Ryan Brown, Founder and CEO of North Bud Farms Inc. “This agreement secures us access to a premier technology partner allowing us to leverage a proven technology and tested processes from an advanced consumer market. We believe this will accelerate NORTHBUD’s goal of developing a food grade cannabinoid infused taste neutral ingredient as a first step towards creating products that will follow in compliance with the upcoming regulations regarding infused consumables. Over the coming months we look forward to working with both Food and Cannabis industry participants as we establish our development platform in preparation for the legalization of edibles and consumables which is anticipated in October 2019.”

“Made By Science has been relentlessly innovating the science driving the infused edibles industry to provide brands and consumers with safe, efficient and accurate products. As our team continues to position as a best in class manufacturer in the U.S., we have had our sights set on Canada as both critical to our long-term expansion and essential for our ability to export to international markets. NORTHBUD was an early believer in our technology and our team and we are excited to support their efforts with innovation and scale,” said Joshua Held, President of Form Factory Inc.

In accordance with the corporate stock option plan, North Bud Farms has issued 85,000 options at a strike price of $0.60 to advisors and consultants assisting with this project. These options will vest over a 24-month period.

About Made By Science Inc.
Made By Science Inc. is a wholly owned subsidiary of Form Factory Inc., a multi state manufacturer of cannabis infused food and beverage products.

For more information visit: www.madebyscience.co

About North Bud Farms Inc.
North Bud Farms Inc., through its wholly-owned subsidiary GrowPros MMP Inc. which was acquired in February 2018, is pursuing a license under the Access to Cannabis for Medical Purposes Regulations (ACMPR).   North Bud Farms will be constructing a state-of-the-art purpose-built cannabis production facility located on 95 acres of Agricultural Land in Low, Quebec. North Bud Farms will be focused on Pharmaceutical and Food Grade cannabinoid production in preparation for the legalization of edibles and ingestible products scheduled for October 2019.

For more information visit: www.northbud.com

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farms’ final long form prospectus dated August 21, 2018 which is available under the issuer’s SEDAR profile at www.sedar.com.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected]

Bougainville Venture’s $BOG.ca Oroville, WA Cultivation Facility Ready for Occupancy $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 1:02 PM on Thursday, September 27th, 2018

681747 5720 copy 2

  • Cultivation facility in Oroville, WA will be occupied by a Tier-3, I-502 tenant within the next weeks
  • The tenant is in the final process of obtaining approval of plans and issuance of permits from Okanogan County and Washington State Liquor Cannabis Board (WSLCB)

Vancouver, BC / September 27, 2018 – BOUGAINVILLE VENTURES INC. (“Bougainville” or the “Company”) (CSE: BOG), providing cannabis infrastructure and seed-to-sale services to I-502 tenant-growers, is pleased to announce that its cultivation facility in Oroville, WA will be occupied by a Tier-3, I-502 tenant within the next weeks. The tenant is in the final process of obtaining approval of plans and issuance of permits from Okanogan County and Washington State Liquor Cannabis Board (WSLCB).

Our Cultivation Facility

Our initial facility is situated on prime farmland in Oroville, WA with easy access to transportation, industrial infrastructure, power, water, gas, and courier services in the northern region of the Okanagan Valley.

The cultivation facility consists of 6 greenhouses providing a total of 30,000 sq. ft. of cultivation area. Three of the greenhouses are complete. Final construction of all 6 greenhouses is expected to be completed in February, 2019.

The Oroville facility is projected to produce in excess of 12,000 lbs. of high quality cannabis per annum upon completion of all the greenhouses.

CEO, Andy Jagpal Comments:

“Our Oroville facilities are now ready for our first tenant to take occupancy. We are also in the final stages of signing other I-502 tenants for this facility. In addition, we are in the process of acquiring new cultivation facilities in other cannabis-approved jurisdictions.”

About Bougainville Ventures, Inc.
Bougainville provides cannabis infrastructure and seed-to-sale services to I-502 tenant-growers leasing greenhouse facilities space and providing fully built-out, turnkey solutions and ancillary services including processing, cannabis expertise and marketing and sales resources. Greenhouse canopies provide a 50% saving in cultivation cost. Bougainville has 30,000 sq ft in near production in Oroville, WA.

For more information please visit: http://bougainvilleinc.com/

 

On behalf of the Board of Directors

BOUGAINVILLE VENTURES INC.

_____________________

Andy Jagpal, CEO and Director

For further information, please contact Andy Jagpal at [email protected] or 1-844-734-8420 ____________

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws, including statements regarding the Oroville, WA cultivation facility: statements pertaining to the ability of Bougainville Ventures Inc. (“BOG”); the anticipated economic potential of the property; the availability of capital and finance for BOG to execute its strategy going forward. Forward-looking statements are based on estimates and assumptions made by BOG in light of its experience and perception of current and expected future developments, as well as other factors that BOG believes are appropriate in the circumstances. Many factors could cause BOG’s results, performance or achievements to differ materially from those expressed or implied by the forward looking statements, including: discrepancies between actual and estimated results from exploration and development and operating risks, dependence on early exploration stage concessions; uninsurable risks; competition; regulatory restrictions, including environmental regulatory restrictions and liability; currency fluctuations; defective title to mineral claims or property and dependence on key employees. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Tetra Bio-Pharma $TBP.ca Announces PPP002 Program Update Following Type B Meeting with U.S. FDA $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:02 AM on Thursday, September 27th, 2018

Logo tetrabiopharma rgb web

  • Announced that it conducted a Type B meeting with the United States Food and Drug Administration (FDA) for its dronabinol AdVersa™Â mucoadhesive product, PPP002
  • The purpose of the meeting was to obtain confirmation of the eligibility of PPP002 for the 505(b)(2) NDA and the requirements for marketing approval

Shorter regulatory pathway confirmed by FDA and potential for Schedule 3 classification

ORLEANS, Ontario, Sept. 27, 2018 — Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that it conducted a Type B meeting with the United States Food and Drug Administration (FDA) for its dronabinol AdVersa™Â mucoadhesive product, PPP002. The purpose of the meeting was to obtain confirmation of the eligibility of PPP002 for the 505(b)(2) NDA and the requirements for marketing approval.

The FDA confirmed the eligibility of the 505(b)(2) regulatory pathway for the product PPP002 and that the efficacy and systemic safety would be supported by the corporation’s proposed comparative bioavailability study and if successful Tetra could apply for FDA approval in Q1 2019, for Chemotherapy Induced Nausea and Vomiting as well as Anorexia associated with Weight Loss in Patients with AIDS. The FDA also provided feedback on the local safety requirements and the evaluation of the abuse potential of PPP002 for obtaining a Schedule III controlled substance classification.

“We are very pleased with the outcome of yesterday’s meeting with the U.S. FDA,” said Guy Chamberland, M.Sc., Ph.D., Interim Chief Executive Officer and CSO of Tetra Bio-Pharma. “The FDA confirmed the shorter regulatory path to the market that Tetra had promised shareholders. In addition, the FDA also provided clear guidance on the safety and drug abuse data requirements for the new drug application. With this confirmation and guidance, Tetra can now complete the execution of the clinical program for PPP002 and, if successful, anticipates submitting a New Drug Application to commercialize PPP002 in Q1 2019.”

According to the International Agency for Research on Cancer1, the global chemotherapy-induced nausea and vomiting (CINV) market will reach a valuation of US$1.88 bn by 2020, an increase from its 2013 valuation of US$1.28 bn. Based on the expected improved safety profile of delayed release dronabinol, Tetra expects that AdVersa™ could gain significant market share within three (3) years of its launch in the USA.

Reducing Opioid Use
The opioid crisis is serious and growing throughout North America. Tetra’s rich cannabinoid-derived product pipeline has the potential to play a significant role in opioid sparing, thus addressing a societal issue of critical proportion. Tetra expects to undertake a Phase II clinical trial using PPP002 up against an opioid to treat chronic pain.

About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the success of PPP002, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact
Energi PR
Carol Levine
514-288-8500 ext. 226
[email protected]
Stephanie Engel
416-425-9143 ext. 209
[email protected]

INTERVIEW: Bougainville Ventures $BOG.ca Discusses Farmland to Greenhouse Conversion $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 12:18 PM on Tuesday, September 25th, 2018

Tetra Bio-Pharma $TBP.ca Takes One Step Closer to the Commercialization of Cannabis Oil-Based Retail Products $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:00 AM on Monday, September 24th, 2018

Logo tetrabiopharma rgb web

  • Made significant progress in its clinical trial for PPP005 the cannabis oil-based capsules destined for the natural health products market
  • Tetra and its clinical research partner, Santé Cannabis, announced that the clinical trial in non-cancer chronic pain patients will be completed later this autumn as promised

ORLEANS, Ontario, Sept. 24, 2018 – Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), has made significant progress in its clinical trial for PPP005 the cannabis oil-based capsules destined for the natural health products market.

Tetra and its clinical research partner, Santé Cannabis, announced that the clinical trial in non-cancer chronic pain patients will be completed later this autumn as promised.  This was the first clinical trial of its kind in evaluating the safety and efficacy of different doses and ratios of cannabis oils versus placebo.  The study included a dose titration phase (gradually bringing patients to the required dose) allowing us to better understand the side effect profile of the oils as well as the development of tolerance to these effects.  Thus far, no other company in the medical cannabis space has undertaken such an exhaustive study to understand the therapeutic benefits and side effects of a cannabis oil-based capsule.

Dr. Chamberland, interim CEO and CSO added, “We continue to deliver on our business model that provides for evidence-based research to support the usage of cannabis-derived products and provide the medical community with the data they have been demanding from this sector. The trial has already provided unique valuable clinical data on both safe and efficacious dose levels of CBD and THC-CBD oils.  This data will allow Tetra to advance to the next phase of product development wherein the company is developing products for its commercial partner Genacol Corporation Canada, as well as food supplements for the retail market and finally, our capsules that we intend to use in the treatment of chronic and cancer related pain.  Tetra has already established itself as a trailblazer in the natural health product segment with the announcement of our intention to launch a Hemp Energy Drink and we intend to build on that momentum.”

About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the success of PPP005, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact
Energi PR
Carol Levine Stephanie Engel
514-288-8500 ext. 226 416-425-9143 ext. 209
[email protected] [email protected]

 

AGORACOM Welcomes North Bud Farms Inc. $NBUD.ca Focusing On Sustainable Low Cost, High Quality Cannabinoid Production

Posted by AGORACOM-JC at 8:43 AM on Friday, September 21st, 2018

Northbud large

WHY NORTH BUD FARMS INC?

  • Canadian regulatory door for CIP (Cannabinoid Infused Products) is opening in 2019
    As shown in other legal jurisdictions (Colorado, Washington, Nevada, California)
  • Infused products sector has become the highest margin segment of the industry
  • Positioned to be a raw input producer for this space
  • Currently working with multiple food, beverage and science companies to provide safe standardized cannabinoid infused raw inputs for large scale GMP manufacturing of products

THE OPPORTUNITY

  • Acquired late stage ACMPR applicant GrowPros
    MMP from Tetra Bio-Pharma (TSXV: TBP)
  • GrowPros MMP application was submitted in November 2014 and is currently in the ‘Confirmation of Readiness’ stage.
  • Phase 1 is located on 95 acres of agricultural farmland in Low, Québec.
  • Option exists to acquire more land if needed
  • Facility will focus on GMP (higher production grade) pharma-grade cultivation and food-grade extracted inputs

LOCATION

SITE DETAILS: LOW COST INFRASTRUCTURE

POSITIONED FOR LEGALIZATION 2.0

  • First mover advantage often becomes first-mover disadvantage
    Examples: AOL, Netscape, Yahoo, BlackBerry
  • Second mover advantage: clearer picture of market and competition
    Examples: Google, Facebook, Amazon, Apple, NORTHBUD

STRATEGIC VERTICALS

Pharma Development

  • North Bud will focus on GMP standardized production to be used by our pharma commercialization partners i.e. Tetra Bio-Pharma We will focus on securing unique strains containing high amounts of specific cannabinoids not typically found in recreational cannabis.

Food Grade Inputs

    • Using our licensed encapsulation technology we will
      engage existing food and beverage companies looking
      to develop product lines containing cannabis.

Tetra Bio-Pharma $TBP.ca Announces Significant Progress on Storz & Bickel Co-Development in Treating #Fibromyalgia $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:09 AM on Thursday, September 20th, 2018

Logo tetrabiopharma rgb web

  • Made significant progress in its co-development partnership with Storz & Bickel
  • The study protocol has received approval from the Independent Ethics Board (IRB Services) and was recently submitted for review to Health Canada

ORLEANS, Ontario, Sept. 20, 2018 — Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), has made significant progress in its co-development partnership with Storz & Bickel.  The study protocol has received approval from the Independent Ethics Board (IRB Services) and was recently submitted for review to Health Canada.  In addition, Tetra Bio-Pharma expects to complete the identification of every compound in the PPP001 vapor generated by the Mighty Medic vaporizer later this month.  Tetra intends on initiating a Phase 1 clinical study in healthy volunteers to determine the safety and pharmacokinetics of its vaporized PPP001 drug later this year.

This clinical data and vapor compound identification will allow Tetra to bridge to its existing and future clinical data of the Phase 3.  The bridge will provide a significantly reduced time to market and reduced development cost for the commercialization of PPP001 as a treatment for fibromyalgia.

“The Independent Ethics Board approval represents a major step forward prior to obtaining approval from Health Canada and the clinical study will allow Tetra to accelerate bringing PPP001 for fibromyalgia patients,” stated Dr. Guy Chamberland, Ph.D., Interim CEO and CSO at Tetra Bio-Pharma.  “We are very confident in Tetra’s strategy to become a global leader in the development of cannabinoid derived prescription and natural health products.”

About Storz & Bickel
STORZ & BICKEL built the first factory in the world for the manufacture of medical herbal vaporizers in Tuttlingen, Germany, a town with almost 500 medical device manufacturers. Tuttlingen is reputed to be the center of medical technology, where the first factory to produce surgical instruments was established more than 150 years ago.

About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the approval of PPP001, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact
Energi PR
Carol Levine
514-288-8500 ext. 226
[email protected]

Stephanie Engel
416-425-9143 ext. 209
[email protected]

North Bud $NBUD.ca Farms to Begin Trading on the Canadian Securities Exchange

Posted by AGORACOM-JC at 8:17 AM on Wednesday, September 19th, 2018

Northbud large

  • will commence trading on the Canadian Securities Exchange at the opening of the market on Thursday, September 20, 2018 under the stock symbol NBUD

TORONTO, Sept. 19, 2018 — North Bud Farms Inc. (“NORTHBUD” or the “Company“) is pleased to announce that its common shares will commence trading on the Canadian Securities Exchange (“CSE”) at the opening of the market on Thursday, September 20, 2018 under the stock symbol “NBUD”.

“We are proud to achieve this milestone in advance of the historic legalization of Cannabis in Canada on October 17, 2018 and less than 10 months since the Company’s inception which is a testament to the dedication and execution of our experienced management team,” said Ryan Brown, Founder and CEO of North Bud Farms.

Concurrently with the CSE listing, the Company also announces that the board of directors has authorized the grant of 5,100,000 incentive stock options to certain of its directors, officers, employees and consultants. Each such option entitles the holder to acquire one common share for a period of 5 years at an exercise price of $0.25 per common share.

About North Bud Farms Inc.
North Bud Farms Inc., through its wholly-owned subsidiary GrowPros MMP Inc. which was acquired from Tetra Bio-Pharma Inc. (TSX-V: TBP) (OTCQB: TBPMF) in February 2018, is pursuing a license under the Access to Cannabis for Medical Purposes Regulations (ACMPR).   North Bud Farms will be constructing a state-of-the-art purpose-built cannabis production facility located on 95 acres of Agricultural Land in Low, Quebec. North Bud Farms will be focused on Pharmaceutical and Food Grade cannabinoid production in preparation for the legalization of edibles and ingestible products scheduled for October 2019.

For more information visit: www.northbud.com

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farms’ final long form prospectus dated August 21, 2018 which is available under the issuer’s SEDAR profile at www.sedar.com.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected]

AGORACOM Welcomes Bougainville Ventures $BOG.ca a Turnkey Greenhouse Growing Infrastructure Provider $MCOA $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 1:48 PM on Monday, September 17th, 2018

681747 5720 copy 2

WHY BOUGAINVILLE?

  • Converting irrigated farmland to greenhouse-equipped farmland
  • Bougainville does not “touch the plant” by only providing agricultural infrastructure as a landlord for licensed marijuana growers
  • First 10,000 square feet of greenhouse space has been completed
  • Ready for occupancy
  • Room for expansion
  • JV Agreement with Marijuana Company of America (MCOA:OTC)
  • MCOA invested $1M in cash

Early estimates show a greenhouse can produce twice the amount of product and at least
less than 50% of the cost compared to warehouse production.

Oroville, Washington

  • Construction complete of a 10,000 sq. ft. greenhouse optimized for low-carbon and sustainable operations
  • I-502 compliant property ready for tenant-grower occupancy
  • 50% + senior water right holder on the main stem of the Eden Valley Aquifer and two supplemental groundwater wells
  • Entered into a lease agreement with a Tier 3 I-502 production and processing license holder
  • Leadership has local farming knowledge and relationships in this region
  • Room for further expansion

Turnkey Growing Facilities

Development Phases

 

Legalized States – Cannabis legalization is spreading across the Nation.

Industry estimates show $27 billion in infrastructure will be needed to meet a full legal US market and Washington State alone will need $679 million in infrastructure.

Market Overview

  • Currently up to 650,000 recreational marijuana users in Washington State, worth approximately $1.5 Billion USD in annual sales.
  • Beyond the traditional uses for cannabis, the industry has benefited from edibles and CBD/THC products for medical use.
  • Upward trajectory of growth in the U.S. market is positively forecasted for years to come.

I-502 License Holders Current Challenges

Health Canada Reclassifies Tetra Bio-Pharma’s $TBP.ca Inhalation Device Making it Eligible for Reimbursement $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:20 AM on Thursday, September 13th, 2018

Logo tetrabiopharma rgb web

  • Health Canada has re-classified the inhalation pipe device used in the delivery of its PPP001 cannabis drug to a Class 2 Medical Device
  • The reclassification will help pave the way towards reimbursement for patients; a key element to patient access and care
  • Significance of this decision is such that if PPP001 is approved by Health Canada, both the prescription drug and the inhalation device will be eligible for insurance coverage by private and provincial public insurance plans

ORLEANS, Ontario, Sept. 13, 2018 – Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, announced today that Health Canada has re-classified the inhalation pipe device used in the delivery of its PPP001 cannabis drug to a Class 2 Medical Device.  The reclassification will help pave the way towards reimbursement for patients; a key element to patient access and care. The significance of this decision is such that if PPP001 is approved by Health Canada, both the prescription drug and the inhalation device will be eligible for insurance coverage by private and provincial public insurance plans.  Tetra Bio-Pharma is undertaking a Phase III trial with PPP001 treating late stage cancer patients looking to improve quality of life and reduce pain.  The Company also recently announced it is starting a head to head trial to investigate cannabis versus Fentanyl in managing breakthrough cancer pain.

“We are very excited by the reclassification as we believe it will provide patients with a financial benefit in terms of coverage for the device and prescription drug,” stated Dr. Guy Chamberland, Ph.D., Interim CEO and CSO at Tetra Bio-Pharma. “Many cancer patients rely on private and public insurance plans for access to their medication.  This decision by the Government of Canada is an important step forward to facilitating access to cannabis drugs. This coupled with our robust clinical trial program and the evidence we are establishing will support physicians in discussing and recommending this option with their patients.”

Dr. Chamberland further stated, “the lack of scientific data on the safety and efficacy of cannabis is a critical barrier to patient access, and something that Canadian physicians are waiting for before being comfortable to prescribe it. Equally essential is adhering to the highest standards of drug manufacturing as well as the production of the delivery mechanism – something that Tetra is committed to.  There are more than 300,000 registered users of medical cannabis in the country and we can only expect this number to rise.”

Tetra has been a pioneer in the development of several cannabis drugs. To date, the Corporation has completed several safety and pharmacokinetic studies in healthy volunteers obtaining proper dosing information and a clear understanding of the potential cardiovascular and neurological risks to patients. This information is critical to protect public health, and Tetra Bio-Pharma is engaged with Health Canada to comply with the highest drug safety standards.

About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the approval of PPP001, insurance coverage for products being developed, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact
Energi PR
Carol Levine Stephanie Engel
514-288-8500 ext. 226 416-425-9143 ext. 209
[email protected] [email protected]